Novel Therapeutics for Pancreatic Adenocarcinoma
Novel Therapeutics for Pancreatic Adenocarcinoma
复制标题
DOI：
10.1016/j.hoc.2015.04.006
复制
发表时间：
2015-08-01
影响因子：
2.4
通讯作者：
O'Reilly, Eileen M.
中科院分区：
文献类型：
--
作者：
Lowery, Maeve A.;O'Reilly, Eileen M.
在过去的十年中，晚期胰腺导管腺癌(PDAC)的联合全身治疗取得了重大进展，在转移的情况下接受FOLFIRINOX治疗的特定患者的中位生存期接近一年。然而，发人深省的是，这些发展是通过使用传统的细胞毒素实现的，而不是通过分子靶向治疗或免疫治疗等更现代领域的成功而实现的。本文重点介绍了目前正在进行临床评估的几种有希望的PDAC治疗方法，包括免疫治疗、分子靶向治疗、基质耗竭策略以及针对遗传选择的患者的靶向治疗。
The last decade has seen significant developments in the use of combination systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC), with median survival approaching 1 year for select patients treated with FOLFIRINOX in the metastatic setting. However, it is sobering that these developments have been achieved with the use of traditional cytotoxics rather than from successes in the more modern fields of molecularly targeted therapies or immunotherapy. This article highlights several promising therapeutic approaches to PDAC currently under clinical evaluation, including immune therapies, molecularly targeted therapies, strategies for stromal depletion, and targeted therapy for genetically selected patients.